Cosentyx Use in Pregnancy: Official Guidance
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, lacks large-scale human pregnancy data. Animal studies show no direct harm to fetuses at doses up to 48 times human levels, but monoclonal antibodies like Cosentyx cross the placenta, especially in the third trimester, raising theoretical risks to fetal immune development.[1][2]
Novartis, the manufacturer, classifies it as Pregnancy Category B (no evidence of risk in animal studies, but inadequate human data). The product label recommends avoiding use during pregnancy unless benefits outweigh risks, and enrolling in the Novartis Pregnancy Registry (1-877-311-8972 in the US) if exposure occurs.[1]
Breastfeeding While on Cosentyx
Secukinumab appears in breast milk at low levels. No data exists on effects on nursing infants, but given its large molecular size, absorption is likely minimal. Weigh risks to the infant against maternal benefits; consider pumping and discarding milk or using formula if concerned.[1][2]
Key Precautions for Patients
- Contraception: Women of childbearing potential should use effective birth control during treatment and for at least 20 weeks after the last dose, as IgG antibodies persist in circulation.[1]
- Pre-treatment Planning: Discuss family planning with your doctor before starting. Discontinue if pregnancy is confirmed, unless clinically essential.
- Monitoring: Report pregnancy immediately for registry enrollment, which tracks outcomes. No increased malformation risk noted in limited post-marketing reports (over 400 exposures).[2]
- Risks to Consider: Potential for newborn immunosuppression (e.g., higher infection risk). Live vaccines are contraindicated for exposed infants for up to 4 months post-birth.[1]
Clinical Data and Real-World Outcomes
Limited studies (e.g., from psoriasis registries) show no clear increase in miscarriage, preterm birth, or congenital anomalies compared to general population rates. A 2023 review of 96 exposed pregnancies found outcomes similar to unexposed (live births: 74%). However, data gaps persist due to small sample sizes.[3]
Alternatives During Pregnancy
Topical treatments or phototherapy are often preferred for psoriasis flares. Systemic options like methotrexate are contraindicated; biologics like etanercept have more pregnancy data but still carry uncertainties. Consult a specialist for individualized switches.[2]
[1]: Cosentyx Prescribing Information (Novartis, 2024)
[2]: Drugs in Pregnancy and Lactation (Briggs et al., 12th ed.)
[3]: MotherToBaby Fact Sheet on Secukinumab